Hospitex International initiates a feasibility study in Uzbekistan for Urine24

Hospitex International, a subsidiary of Aliko Scientific, has signed an agreement with the Uzbek Oncology Institute for a feasibility study of Urine24. This initiative aims to roll out the urinary tract cancer screening project nationwide. The agreement reflects the growing interest in Urine24, Hospitex's screening model, and highlights Aliko's expertise in oncology diagnostics.

The study will cover technical, operational, regulatory, financial, and organizational aspects. The first potential phase is estimated at one million euros, subject to the study's positive results. This collaboration aligns with Aliko's strategy to promote diagnostic solutions internationally.